CZ304734B6 - Způsob přípravy 9-[2-(fosfonomethoxy)propyl]adeninu a 9-[2-(fosfonomethoxy)ethyl]adeninu - Google Patents
Způsob přípravy 9-[2-(fosfonomethoxy)propyl]adeninu a 9-[2-(fosfonomethoxy)ethyl]adeninu Download PDFInfo
- Publication number
- CZ304734B6 CZ304734B6 CZ2013-310A CZ2013310A CZ304734B6 CZ 304734 B6 CZ304734 B6 CZ 304734B6 CZ 2013310 A CZ2013310 A CZ 2013310A CZ 304734 B6 CZ304734 B6 CZ 304734B6
- Authority
- CZ
- Czechia
- Prior art keywords
- adenine
- phosphonomethoxy
- propyl
- ethyl
- mol
- Prior art date
Links
- SUPKOOSCJHTBAH-UHFFFAOYSA-N adefovir Chemical compound NC1=NC=NC2=C1N=CN2CCOCP(O)(O)=O SUPKOOSCJHTBAH-UHFFFAOYSA-N 0.000 title claims abstract description 6
- SGOIRFVFHAKUTI-UHFFFAOYSA-N 1-(6-aminopurin-9-yl)propan-2-yloxymethylphosphonic acid Chemical compound N1=CN=C2N(CC(C)OCP(O)(O)=O)C=NC2=C1N SGOIRFVFHAKUTI-UHFFFAOYSA-N 0.000 title claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 title abstract description 3
- 239000011777 magnesium Substances 0.000 claims abstract description 6
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 6
- -1 magnesium alkoxide Chemical class 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 7
- VAQOTZQDXZDBJK-UHFFFAOYSA-N 2-(6-aminopurin-9-yl)ethanol Chemical compound NC1=NC=NC2=C1N=CN2CCO VAQOTZQDXZDBJK-UHFFFAOYSA-N 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- LVOASXNJWPROPP-UHFFFAOYSA-N (4-methylphenyl)sulfonyloxymethylphosphonic acid Chemical compound CC1=CC=C(S(=O)(=O)OCP(O)(O)=O)C=C1 LVOASXNJWPROPP-UHFFFAOYSA-N 0.000 claims description 3
- MJZYTEBKXLVLMY-UHFFFAOYSA-N 1-(6-aminopurin-9-yl)propan-2-ol Chemical compound N1=CN=C2N(CC(O)C)C=NC2=C1N MJZYTEBKXLVLMY-UHFFFAOYSA-N 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 150000004703 alkoxides Chemical class 0.000 claims 3
- NMNFDTCOWIDEAV-UHFFFAOYSA-N OP(O)=O.OP(O)=O Chemical compound OP(O)=O.OP(O)=O NMNFDTCOWIDEAV-UHFFFAOYSA-N 0.000 claims 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 9
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229930024421 Adenine Natural products 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
- 229960000643 adenine Drugs 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- ORPJQHHQRCLVIC-UHFFFAOYSA-N magnesium;propan-2-olate Chemical compound CC(C)O[Mg]OC(C)C ORPJQHHQRCLVIC-UHFFFAOYSA-N 0.000 description 3
- 239000012265 solid product Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- RTKCPZYOLXPARI-UHFFFAOYSA-N magnesium;2-methylpropan-2-olate Chemical compound [Mg+2].CC(C)(C)[O-].CC(C)(C)[O-] RTKCPZYOLXPARI-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- MJZYTEBKXLVLMY-RXMQYKEDSA-N (2r)-1-(6-aminopurin-9-yl)propan-2-ol Chemical compound N1=CN=C2N(C[C@H](O)C)C=NC2=C1N MJZYTEBKXLVLMY-RXMQYKEDSA-N 0.000 description 1
- RUOJZAUFBMNUDX-GSVOUGTGSA-N (4r)-4-methyl-1,3-dioxolan-2-one Chemical compound C[C@@H]1COC(=O)O1 RUOJZAUFBMNUDX-GSVOUGTGSA-N 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- GFPMTTHVYNIDBY-UHFFFAOYSA-N S(=O)(=O)(O)C1=CC=C(C)C=C1.C1(=CC=C(C=C1)S(=O)(=O)OCP(O)(O)=O)C Chemical compound S(=O)(=O)(O)C1=CC=C(C)C=C1.C1(=CC=C(C=C1)S(=O)(=O)OCP(O)(O)=O)C GFPMTTHVYNIDBY-UHFFFAOYSA-N 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- HFTSQAKJLBPKBD-UHFFFAOYSA-N magnesium;butan-1-olate Chemical compound [Mg+2].CCCC[O-].CCCC[O-] HFTSQAKJLBPKBD-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- CAAULPUQFIIOTL-UHFFFAOYSA-N methyl dihydrogen phosphate Chemical class COP(O)(O)=O CAAULPUQFIIOTL-UHFFFAOYSA-N 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- SGOIRFVFHAKUTI-ZCFIWIBFSA-N tenofovir (anhydrous) Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(O)=O)C=NC2=C1N SGOIRFVFHAKUTI-ZCFIWIBFSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 238000007070 tosylation reaction Methods 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22002100P | 2000-07-21 | 2000-07-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CZ304734B6 true CZ304734B6 (cs) | 2014-09-10 |
Family
ID=22821718
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ2013-310A CZ304734B6 (cs) | 2000-07-21 | 2001-07-20 | Způsob přípravy 9-[2-(fosfonomethoxy)propyl]adeninu a 9-[2-(fosfonomethoxy)ethyl]adeninu |
| CZ2003-413A CZ304886B6 (cs) | 2000-07-21 | 2001-07-20 | Prekurzory léčiv na bázi fosfonátových analogů nukleotidů a způsoby jejich výběru a přípravy |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ2003-413A CZ304886B6 (cs) | 2000-07-21 | 2001-07-20 | Prekurzory léčiv na bázi fosfonátových analogů nukleotidů a způsoby jejich výběru a přípravy |
Country Status (37)
Families Citing this family (239)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1301519T1 (sl) * | 2000-07-21 | 2015-07-31 | Gilead Sciences, Inc. | Predzdravila fosfonatnih nukleotidnih analogov in postopki za izbiro in izdelavo le-teh |
| CA2466301A1 (en) * | 2001-11-14 | 2003-10-23 | Biocryst Pharmaceuticals, Inc. | Nucleosides preparation thereof and use as inhibitors of rna viral polymerases |
| US7388002B2 (en) * | 2001-11-14 | 2008-06-17 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| TW200408645A (en) * | 2002-04-26 | 2004-06-01 | Gilead Sciences Inc | Non nucleoside reverse transcriptase inhibitors |
| US20050239054A1 (en) * | 2002-04-26 | 2005-10-27 | Arimilli Murty N | Method and compositions for identifying anti-HIV therapeutic compounds |
| US7214668B2 (en) | 2002-05-13 | 2007-05-08 | Metabasis Therapeutics, Inc. | Phosphonic acid based prodrugs of PMEA and its analogues |
| CA2512475C (en) | 2003-01-14 | 2009-06-02 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
| US7470724B2 (en) * | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
| WO2004096234A2 (en) * | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
| SG182849A1 (en) | 2003-04-25 | 2012-08-30 | Gilead Sciences Inc | Antiviral phosphonate analogs |
| US20050261237A1 (en) * | 2003-04-25 | 2005-11-24 | Boojamra Constantine G | Nucleoside phosphonate analogs |
| US7427636B2 (en) | 2003-04-25 | 2008-09-23 | Gilead Sciences, Inc. | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds |
| US20090247488A1 (en) * | 2003-04-25 | 2009-10-01 | Carina Cannizzaro | Anti-inflammatory phosphonate compounds |
| US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
| CN101410120A (zh) * | 2003-04-25 | 2009-04-15 | 吉里德科学公司 | 抗炎的膦酸酯化合物 |
| US7432261B2 (en) * | 2003-04-25 | 2008-10-07 | Gilead Sciences, Inc. | Anti-inflammatory phosphonate compounds |
| US7407965B2 (en) * | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
| US7300924B2 (en) | 2003-04-25 | 2007-11-27 | Gilead Sciences, Inc. | Anti-infective phosphonate analogs |
| WO2005002626A2 (en) | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
| US7432273B2 (en) | 2003-10-24 | 2008-10-07 | Gilead Sciences, Inc. | Phosphonate analogs of antimetabolites |
| US7427624B2 (en) | 2003-10-24 | 2008-09-23 | Gilead Sciences, Inc. | Purine nucleoside phosphorylase inhibitory phosphonate compounds |
| CA2543144A1 (en) * | 2003-10-24 | 2005-05-12 | Gilead Sciences, Inc. | Methods and compositions for identifying therapeutic compounds |
| BRPI0418031A (pt) * | 2003-12-22 | 2007-04-17 | Gilead Sciences Inc | inibidores de quinase fosfonato-substituìdos |
| US7432272B2 (en) | 2003-12-22 | 2008-10-07 | Gilead Sciences, Inc. | Antiviral analogs |
| US20050153990A1 (en) * | 2003-12-22 | 2005-07-14 | Watkins William J. | Phosphonate substituted kinase inhibitors |
| EP1716162B1 (en) * | 2003-12-30 | 2010-08-18 | Gilead Sciences, Inc. | Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases |
| ATE445404T1 (de) * | 2004-01-21 | 2009-10-15 | Gilead Sciences Inc | Verwendung von adefovir oder tenofovir zur hemmung von mmtv-artigen viren im zusammenhang mit brustkrebs und primärer biliärer zirrhose |
| US7079156B1 (en) | 2004-05-14 | 2006-07-18 | Nvidia Corporation | Method and system for implementing multiple high precision and low precision interpolators for a graphics pipeline |
| US8411105B1 (en) | 2004-05-14 | 2013-04-02 | Nvidia Corporation | Method and system for computing pixel parameters |
| US8416242B1 (en) | 2004-05-14 | 2013-04-09 | Nvidia Corporation | Method and system for interpolating level-of-detail in graphics processors |
| US8432394B1 (en) | 2004-05-14 | 2013-04-30 | Nvidia Corporation | Method and system for implementing clamped z value interpolation in a raster stage of a graphics pipeline |
| CA2565966A1 (en) | 2004-06-08 | 2005-12-29 | Metabasis Therapeutics, Inc. | Lewis acid mediated synthesis of cyclic esters |
| DK1778251T3 (da) | 2004-07-27 | 2011-07-18 | Gilead Sciences Inc | Nukleosidphosphatkonjugater som anti-HIV-midler |
| EP2842559A3 (en) * | 2005-04-08 | 2015-03-18 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of viral infections and other medical disorders |
| US8642577B2 (en) | 2005-04-08 | 2014-02-04 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
| CN100359315C (zh) * | 2005-05-26 | 2008-01-02 | 林维宣 | 兽药残留能力验证样品及制备方法 |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| US8076303B2 (en) | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
| CN100396689C (zh) * | 2006-03-07 | 2008-06-25 | 中国医学科学院医药生物技术研究所 | 一组具有抑制hiv-1/hbv病毒复制活性的替诺福韦单酯化合物 |
| SI2020996T1 (sl) | 2006-05-16 | 2012-03-30 | Gilead Sciences Inc | Postopek in sestavki za zdravljenje hematološkihmalignosti |
| EP2046792B1 (en) * | 2006-07-12 | 2015-02-25 | Mylan Laboratories Limited | Process for the preparation of tenofovir |
| US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| US8105489B2 (en) * | 2007-06-26 | 2012-01-31 | The University Of Wyoming Research Corporation | Treatment and prevention systems for acid mine drainage and halogenated contaminants |
| US8441497B1 (en) * | 2007-08-07 | 2013-05-14 | Nvidia Corporation | Interpolation of vertex attributes in a graphics processor |
| CN105055432A (zh) * | 2008-01-25 | 2015-11-18 | 奇默里克斯公司 | 治疗病毒感染的方法 |
| TWI444384B (zh) | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
| CA2722165C (en) * | 2008-04-25 | 2016-01-19 | Cipla Limited | Crystalline form of tenofovir disoproxil and a process for its preparation |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| JP2011526893A (ja) * | 2008-07-02 | 2011-10-20 | イデニク プハルマセウティカルス，インコーポレイテッド | ウイルス感染の治療のための化合物、及び医薬組成物 |
| JP5620376B2 (ja) | 2008-07-08 | 2014-11-05 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖ阻害剤化合物の塩 |
| SG172363A1 (en) * | 2008-12-23 | 2011-07-28 | Pharmasset Inc | Synthesis of purine nucleosides |
| WO2010075549A2 (en) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Nucleoside phosphoramidates |
| NZ617066A (en) | 2008-12-23 | 2015-02-27 | Gilead Pharmasset Llc | Nucleoside analogs |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| WO2011011519A1 (en) | 2009-07-21 | 2011-01-27 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
| SI2480559T1 (sl) | 2009-09-21 | 2013-10-30 | Gilead Sciences, Inc. | Postopki in intermediati za pripravo 1'-ciano-karbanukleozidnih analogov |
| HUE032860T2 (en) | 2010-02-12 | 2017-11-28 | Chimerix Inc | A method for treating a virus infection |
| ES2516466T3 (es) | 2010-03-31 | 2014-10-30 | Gilead Pharmasset Llc | Síntesis estereoselectiva de agentes activos que contienen fósforo |
| PL3290428T3 (pl) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu |
| JP2013523765A (ja) | 2010-04-01 | 2013-06-17 | イデニク プハルマセウティカルス，インコーポレイテッド | ウイルス感染の治療のための化合物及び医薬組成物 |
| AU2011248620B2 (en) | 2010-04-26 | 2015-11-26 | Chimerix, Inc. | Methods of treating retroviral infections and related dosage regimes |
| PH12013500033A1 (en) | 2010-07-19 | 2017-07-26 | Gilead Sciences Inc | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| US20120027752A1 (en) | 2010-07-22 | 2012-02-02 | Gilead Sciences, Inc. | Methods and compounds for treating paramyxoviridae virus infections |
| AU2011336632B2 (en) | 2010-11-30 | 2015-09-03 | Gilead Pharmasset Llc | Compounds |
| CN103338754A (zh) | 2010-12-10 | 2013-10-02 | 西格玛制药实验有限责任公司 | 口服活性核苷酸类似物或口服活性核苷酸类似物前药的高度稳定组合物 |
| ZA201103820B (en) | 2010-12-13 | 2012-01-25 | Laurus Labs Private Ltd | Process for the preparation of tenofovir |
| CN103842369A (zh) | 2011-03-31 | 2014-06-04 | 埃迪尼克斯医药公司 | 用于治疗病毒感染的化合物和药物组合物 |
| WO2012154698A2 (en) * | 2011-05-06 | 2012-11-15 | Mckenna Charles E | Method to improve antiviral activity of nucleotide analogue drugs |
| PT3199537T (pt) | 2011-05-19 | 2019-01-17 | Gilead Sciences Inc | Processos e intermediários para preparar agentes anti-hiv |
| BR112014003420B1 (pt) * | 2011-08-16 | 2021-07-20 | Gilead Sciences, Inc | Hemifumarato de tenofovir alafenamida. composição, seus métodos de preparação e uso |
| AU2014271320B2 (en) * | 2011-08-16 | 2017-02-23 | Gilead Sciences, Inc. | Tenofovir alafenamide hemifumarate |
| WO2013040492A2 (en) | 2011-09-16 | 2013-03-21 | Gilead Sciences, Inc. | Methods for treating hcv |
| AU2012319172B2 (en) | 2011-10-07 | 2014-06-12 | Gilead Sciences, Inc. | Methods for preparing anti-viral nucleotide analogs |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| JP6113185B2 (ja) | 2011-12-22 | 2017-04-12 | ジェロン・コーポレーションＧｅｒｏｎ Ｃｏｒｐｏｒａｔｉｏｎ | テロメラーゼ基質およびテロメア長作用因子としてのグアニンアナログ |
| WO2013115916A1 (en) | 2012-02-03 | 2013-08-08 | Gilead Sciences, Inc. | Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections |
| CN104105484A (zh) | 2012-02-03 | 2014-10-15 | 吉联亚科学公司 | 用于治疗病毒感染的包含替诺福韦艾拉酚胺半反丁烯二酸盐和可比西他的组合疗法 |
| CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
| GB201215696D0 (en) * | 2012-09-03 | 2012-10-17 | Ithemba Pharmaceuticals Pty Ltd | A process for the preparation of (R)-9-[2-(Phosphonometh-Oxy)propyl]adenine (PMPA) |
| KR102186030B1 (ko) * | 2012-10-29 | 2020-12-03 | 시플라 리미티드 | 항 바이러스성 포스포네이트 유사체 및 이의 제조를 위한 방법 |
| CN102899327B (zh) * | 2012-11-06 | 2014-06-11 | 清华大学深圳研究生院 | 一种抗病毒的小核酸及其温度敏感型凝胶制剂与应用 |
| EP2920171B1 (en) * | 2012-11-16 | 2018-08-29 | Merck Sharp & Dohme Corp. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
| CN103848869B (zh) * | 2012-12-04 | 2016-12-21 | 上海医药工业研究院 | 制备替诺福韦的方法 |
| CN103848868B (zh) * | 2012-12-04 | 2017-04-12 | 蚌埠丰原涂山制药有限公司 | 制备替诺福韦的方法 |
| SG10201706949VA (en) | 2013-01-31 | 2017-09-28 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| CN104072539B (zh) * | 2013-03-25 | 2017-03-29 | 安徽贝克联合制药有限公司 | 替诺福韦双(4‑乙酰氨基苯酚氧基)酯及其制备方法和其应用 |
| EP3000898B1 (en) * | 2013-05-21 | 2020-11-18 | Hitgen Inc. | Drug target capturing method |
| EP3004121A1 (en) | 2013-06-07 | 2016-04-13 | Cipla Limited | An efficient process for separation of diastereomers of 9-[(r)-2-[[(r,s)-[[(s)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine |
| PL3650014T3 (pl) | 2013-08-27 | 2022-01-31 | Gilead Pharmasset Llc | Preparat złożony dwóch związków przeciwwirusowych |
| WO2015040640A2 (en) * | 2013-09-20 | 2015-03-26 | Laurus Labs Private Limited | An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof |
| EP2860185A1 (en) | 2013-10-09 | 2015-04-15 | Zentiva, k.s. | An improved process for the preparation of Tenofovir disoproxil and pharmaceutically acceptable salts thereof |
| WO2015079455A2 (en) * | 2013-11-27 | 2015-06-04 | Laurus Labs Private Limited | A recycling process for preparing tenofovir alafenamide diastereomers |
| IN2014MU00118A (Direct) * | 2014-01-14 | 2015-08-28 | Mylan Lab Ltd | |
| TWI660965B (zh) * | 2014-01-15 | 2019-06-01 | 美商基利科學股份有限公司 | 泰諾福韋之固體形式 |
| CN104804042B (zh) * | 2014-01-24 | 2018-01-19 | 齐鲁制药有限公司 | 核苷酸膦酸酯类化合物、其药物组合物、制备方法及用途 |
| WO2015120057A1 (en) | 2014-02-05 | 2015-08-13 | Gilead Sciences, Inc. | Pharmaceutical combinations against co-infection with hiv and tuberculosis |
| US10449210B2 (en) * | 2014-02-13 | 2019-10-22 | Ligand Pharmaceuticals Inc. | Prodrug compounds and their uses |
| WO2015127848A1 (zh) * | 2014-02-27 | 2015-09-03 | 四川海思科制药有限公司 | 一种取代的氨基磷酸酯类衍生物、其制备方法及其应用 |
| CN105001262B (zh) * | 2014-04-18 | 2017-09-01 | 四川海思科制药有限公司 | 芳基取代的磷酰胺类衍生物及其在医学上的应用 |
| CN105531281B (zh) * | 2014-04-21 | 2017-12-15 | 四川海思科制药有限公司 | 一种核苷类似物及其中间体的制备方法 |
| CN105085571A (zh) * | 2014-05-20 | 2015-11-25 | 四川海思科制药有限公司 | 替诺福韦艾拉酚胺复合物及其制备方法和用途 |
| CN105518012B (zh) * | 2014-06-25 | 2018-03-02 | 四川海思科制药有限公司 | 一种取代的氨基酸硫酯类化合物、其组合物及应用 |
| JP2017520545A (ja) | 2014-07-02 | 2017-07-27 | リガンド・ファーマシューティカルズ・インコーポレイテッド | プロドラッグ化合物およびそれらの使用 |
| ES2915381T3 (es) | 2014-09-15 | 2022-06-22 | Univ California | Análogos de nucleótidos |
| KR101703257B1 (ko) | 2014-09-30 | 2017-02-06 | 한미정밀화학주식회사 | 고순도의 (r)-9-[2-(포스포노메톡시)프로필]아데닌의 제조방법 |
| KR101703258B1 (ko) | 2014-12-30 | 2017-02-06 | 한미정밀화학주식회사 | 고순도의 (r)-9-[2-(포스포노메톡시)프로필]아데닌의 제조방법 |
| WO2016052930A1 (ko) * | 2014-09-30 | 2016-04-07 | 한미정밀화학주식회사 | 고순도의 (r)-9-[2-(포스포노메톡시)프로필]아데닌의 제조방법 |
| EP3203995A4 (en) | 2014-10-09 | 2019-05-15 | Board of Regents of the University of Nebraska | COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS |
| TWI698444B (zh) | 2014-10-29 | 2020-07-11 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
| CN105646584B (zh) * | 2014-11-12 | 2018-09-28 | 四川海思科制药有限公司 | 替诺福韦艾拉酚胺富马酸盐晶型及其制备方法和用途 |
| CN104558036A (zh) * | 2014-12-11 | 2015-04-29 | 杭州和泽医药科技有限公司 | 一种替诺福韦艾拉酚胺半反丁烯二酸盐晶型及其制备方法 |
| WO2016108205A1 (en) | 2015-01-03 | 2016-07-07 | Mylan Laboratories Limited | Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof |
| US20180148774A1 (en) * | 2015-05-16 | 2018-05-31 | Godx, Inc | Point of need testing device and methods of use thereof |
| CN106188139B (zh) * | 2015-05-29 | 2020-02-18 | 江苏天士力帝益药业有限公司 | 替诺福韦单苄酯磷酸酰胺前药、其制备方法及应用 |
| CZ2015384A3 (cs) | 2015-06-05 | 2016-12-14 | Zentiva, K.S. | Pevné formy Tenofovir alafenamidu |
| AU2016277859B2 (en) * | 2015-06-17 | 2019-08-01 | Gilead Sciences, Inc. | Co-crystals, salts and solid forms of tenofovir alafenamide |
| EP3316868B1 (en) | 2015-06-30 | 2020-02-19 | Gilead Sciences, Inc. | Pharmaceutical formulations comprising tenofovir and emtricitabine |
| CN107849071B (zh) | 2015-08-10 | 2021-03-09 | 默沙东公司 | 抗病毒的β氨基酸酯膦酰二胺化合物 |
| TWI620754B (zh) * | 2015-08-26 | 2018-04-11 | Method for preparing amino phosphate derivative and preparation method thereof | |
| TWI616452B (zh) * | 2015-08-26 | 2018-03-01 | Preparation method of nucleoside analog and intermediate thereof | |
| TWI616453B (zh) * | 2015-08-27 | 2018-03-01 | Substituted amino acid thioester compounds, compositions and uses thereof | |
| WO2017037608A1 (en) * | 2015-08-28 | 2017-03-09 | Laurus Labs Private Limited | Solid forms of tenofovir alafenamide and salts thereof, processes for its preparation and pharmaceutical compositions thereof |
| LT3785717T (lt) | 2015-09-16 | 2022-04-11 | Gilead Sciences, Inc. | Coronaviridae infekcijų gydymo būdai |
| KR102153996B1 (ko) | 2015-11-09 | 2020-09-09 | 길리애드 사이언시즈, 인코포레이티드 | 인간 면역결핍 바이러스의 치료를 위한 치료 조성물 |
| CN106800573B (zh) * | 2015-11-25 | 2020-03-10 | 四川海思科制药有限公司 | 一种核苷酸膦酸酯一水合物及其制备方法和在医药上的应用 |
| US10745428B2 (en) | 2015-12-10 | 2020-08-18 | Idenix Pharmaceuticals Llc | Antiviral phosphodiamide prodrugs of tenofovir |
| CN106866737B (zh) * | 2015-12-11 | 2020-11-20 | 南京圣和药物研发有限公司 | 膦酸衍生物及其应用 |
| WO2017106069A1 (en) | 2015-12-15 | 2017-06-22 | Merck Sharp & Dohme Corp. | Antiviral oxime phosphoramide compounds |
| WO2017118928A1 (en) | 2016-01-06 | 2017-07-13 | Lupin Limited | Process for the separation of diastereomers of tenofovir alafenamide |
| ES2806604T3 (es) | 2016-02-02 | 2021-02-18 | Sandoz Ag | Formas cristalinas de monofumarato de tenofovir alafenamida |
| CN107709288A (zh) * | 2016-02-03 | 2018-02-16 | 四川海思科制药有限公司 | 一种磷酰胺衍生物及制备方法和用途 |
| CN108350007B (zh) * | 2016-03-01 | 2020-04-10 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的腺嘌呤化合物及其药物组合物 |
| CN107179355B (zh) * | 2016-03-11 | 2021-08-10 | 广东东阳光药业有限公司 | 一种分离检测替诺福韦艾拉酚胺及其有关物质的方法 |
| CZ2016156A3 (cs) | 2016-03-17 | 2017-09-27 | Zentiva, K.S. | Způsob přípravy diastereomerně čistého Tenofoviru Alafenamidu nebo jeho solí |
| CN107226826A (zh) * | 2016-03-25 | 2017-10-03 | 江苏奥赛康药业股份有限公司 | 替诺福韦艾拉酚胺富马酸盐化合物及其药物组合物 |
| CN109476689B (zh) | 2016-06-05 | 2021-09-03 | 上海诚妙医药科技有限公司 | 富马酸替诺福韦艾拉酚胺盐的新晶型、制备方法及其用途 |
| CN107698621A (zh) * | 2016-06-20 | 2018-02-16 | 杭州和泽医药科技有限公司 | 一种腺嘌呤衍生物的膦酸酯前药及其在医药上的应用 |
| WO2017221189A1 (en) * | 2016-06-22 | 2017-12-28 | Laurus Labs Limited | An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof |
| CN106317116A (zh) * | 2016-08-19 | 2017-01-11 | 张红利 | 磷酰胺核苷类化合物及其药学上可接受的盐与应用、药物组合物 |
| MX369307B (es) | 2016-08-19 | 2019-11-05 | Gilead Sciences Inc | Compuestos terapeuticos utiles para tratamiento profilactico o terapeutico de infeccion por virus de inmunodeficiencia humana. |
| US10449208B2 (en) | 2016-08-25 | 2019-10-22 | Merck Sharp & Dohme Corp. | Antiviral prodrugs of tenofovir |
| CN106380484A (zh) * | 2016-08-29 | 2017-02-08 | 杭州百诚医药科技股份有限公司 | 一种替诺福韦艾拉酚胺的新晶型及其制备方法 |
| WO2018042331A1 (en) | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations and uses and treatments thereof |
| WO2018051250A1 (en) | 2016-09-14 | 2018-03-22 | Viiv Healthcare Company | Combination comprising tenofovir alafenamide, bictegravir and 3tc |
| WO2018080903A1 (en) | 2016-10-26 | 2018-05-03 | Merck Sharp & Dohme Corp. | Antiviral aryl-amide phosphodiamide compounds |
| CN106565785B (zh) * | 2016-11-09 | 2019-11-12 | 周雨恬 | 一种具有抗hbv/hiv活性的核苷氨基磷酸酯类化合物及其盐和用途 |
| CN108129514A (zh) * | 2016-12-01 | 2018-06-08 | 北京美倍他药物研究有限公司 | 磷酸/膦酸衍生物的单一异构体及其医药用途 |
| MA47131A (fr) | 2016-12-22 | 2021-05-12 | Idenix Pharmaceuticals Llc | Composés benzyl-amide phosphodiamide antiviraux |
| WO2018119013A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antiviral aliphatic ester prodrugs of tenofovir |
| WO2018115046A1 (en) | 2016-12-23 | 2018-06-28 | Sandoz Ag | Crystalline solid forms of tenofovir alafenamide |
| TWI784370B (zh) | 2017-01-31 | 2022-11-21 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
| WO2018153977A1 (en) | 2017-02-24 | 2018-08-30 | Hexal Ag | Stable composition of tenofovir alafenamide |
| US20190374557A1 (en) * | 2017-02-28 | 2019-12-12 | Alexandre Vasilievich Ivachtchenko | Cyclobutyl (S)-2-[[[(R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-phenoxy-phosphoryl]amino]-propanoates, and production process and application thereof |
| RU2659388C1 (ru) | 2017-02-28 | 2018-07-02 | Васильевич Иващенко Александр | Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение |
| CN106866739B (zh) * | 2017-03-10 | 2018-11-02 | 华东师范大学 | 一种(r)-1-(6-氨基-9h-嘌呤-9-基)2-苯酯的制备方法 |
| KR102318320B1 (ko) | 2017-03-14 | 2021-10-27 | 길리애드 사이언시즈, 인코포레이티드 | 고양이 코로나바이러스 감염의 치료 방법 |
| WO2018175325A1 (en) | 2017-03-20 | 2018-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv post-exposure prophylaxis |
| CN108794530A (zh) * | 2017-04-26 | 2018-11-13 | 上海医药工业研究院 | 一种替诺福韦丙酚酰胺盐晶型及其制备方法和用途 |
| US10836787B2 (en) | 2017-05-01 | 2020-11-17 | Gilead Sciences, Inc. | Crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5- (4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| KR102379965B1 (ko) * | 2017-05-19 | 2022-03-29 | 주식회사 종근당 | 테노포비르의 효율적인 제조방법 |
| CN107266499B (zh) * | 2017-06-05 | 2019-07-02 | 珠海优润医药科技有限公司 | 一种抗病毒化合物及其制备方法 |
| WO2019003251A1 (en) | 2017-06-30 | 2019-01-03 | Cipla Limited | PHARMACEUTICAL COMPOSITIONS |
| CN111093627B (zh) | 2017-07-11 | 2024-03-08 | 吉利德科学公司 | 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物 |
| WO2019021319A1 (en) | 2017-07-27 | 2019-01-31 | Cipla Limited | PHARMACEUTICAL COMPOSITIONS |
| ES2969496T3 (es) | 2017-08-01 | 2024-05-20 | Gilead Sciences Inc | Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2- il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| CN107655987B (zh) * | 2017-09-08 | 2020-11-03 | 厦门蔚扬药业有限公司 | 一种替诺福韦艾拉酚胺及其异构体的hplc检测方法 |
| CN107522743A (zh) * | 2017-09-30 | 2017-12-29 | 深圳科兴生物工程有限公司 | 一种半富马酸替诺福韦艾拉酚胺工业化连续生产方法 |
| EP3700573A1 (en) | 2017-10-24 | 2020-09-02 | Gilead Sciences, Inc. | Methods of treating patients co-infected with a virus and tuberculosis |
| CN109942632B (zh) * | 2017-12-20 | 2021-08-31 | 上海博志研新药物研究有限公司 | 替诺福韦艾拉酚胺中间体的制备方法 |
| CN109942633B (zh) * | 2017-12-20 | 2021-08-31 | 上海新礼泰药业有限公司 | 替诺福韦艾拉酚胺中间体的制备方法 |
| US20200407382A1 (en) | 2017-12-30 | 2020-12-31 | Cipla Limited | Polymorphic forms of (9-[(r)-2-[[(s)-[[(s)-1-(isopropoxycarbonyl)ethyl]amino]phenoxy phosphinyl]methoxy]propyl] adenine and pharmaceutically acceptable salts thereof |
| US11970482B2 (en) | 2018-01-09 | 2024-04-30 | Ligand Pharmaceuticals Inc. | Acetal compounds and therapeutic uses thereof |
| MX2020007393A (es) * | 2018-01-10 | 2020-11-24 | Nucorion Pharmaceuticals Inc | Compuestos de fósforo(n)amidatacetal y fosf(on)atalcetal. |
| WO2019140365A1 (en) * | 2018-01-12 | 2019-07-18 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and formulations thereof |
| EP3752495B1 (en) | 2018-02-15 | 2023-07-19 | Gilead Sciences, Inc. | Pyridine derivatives and their use for treating hiv infection |
| CA3281991A1 (en) | 2018-02-16 | 2025-11-29 | Gilead Sciences, Inc. | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviridae viral infection |
| CN108101943B (zh) * | 2018-02-28 | 2020-11-24 | 顾世海 | 一种替诺福韦前药或可药用盐及其在医药上的应用 |
| CA3132832A1 (en) | 2018-04-09 | 2019-10-17 | Howard E. Gendelman | Antiviral prodrugs and formulations thereof |
| KR20230141905A (ko) | 2018-07-16 | 2023-10-10 | 길리애드 사이언시즈, 인코포레이티드 | Hiv의 치료를 위한 캡시드 억제제 |
| EP3823629B1 (en) | 2018-07-19 | 2024-12-25 | Merck Sharp & Dohme LLC | Phosphinic amide prodrugs of tenofovir |
| KR102879944B1 (ko) | 2018-09-19 | 2025-11-03 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 예방용 인테그라제 억제제 |
| HRP20221074T1 (hr) | 2019-03-22 | 2022-11-11 | Gilead Sciences, Inc. | Premošteni triciklički spojevi karbamoilpiridona i njihove farmaceutske uporabe |
| KR20220035143A (ko) | 2019-07-17 | 2022-03-21 | 누코리온 파마슈티컬스, 인코포레이티드. | 사이클릭 디옥시리보뉴클레오티드 화합물 |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| US20220265689A1 (en) | 2019-07-19 | 2022-08-25 | THE UNITED STATES OF AMERICA , as represented by the Secretary, Department of Health and Human | Hiv pre-exposure prophylaxis |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| AU2020334152A1 (en) * | 2019-08-22 | 2022-03-24 | Emory University | Nucleoside prodrugs and uses related thereto |
| EP4031141A4 (en) * | 2019-09-20 | 2023-10-18 | Abbott Rapid Diagnostics International Unlimited Company | ANTIBODIES TO TENOFOVIR AND DERIVATIVES THEREOF |
| EP4065116A1 (en) | 2019-11-26 | 2022-10-05 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of hiv |
| WO2021154687A1 (en) | 2020-01-27 | 2021-08-05 | Gilead Sciences, Inc. | Methods for treating sars cov-2 infections |
| WO2021165995A1 (en) | 2020-02-20 | 2021-08-26 | Cipla Limited | Novel salts and/or co-crystals of tenofovir alafenamide |
| WO2021183750A2 (en) | 2020-03-12 | 2021-09-16 | Gilead Sciences, Inc. | Methods of preparing 1'-cyano nucleosides |
| US11718637B2 (en) | 2020-03-20 | 2023-08-08 | Gilead Sciences, Inc. | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same |
| WO2021202669A2 (en) | 2020-04-01 | 2021-10-07 | Reyoung Corporation | Nucleoside and nucleotide conjugate compounds and uses thereof |
| AU2021251689B2 (en) | 2020-04-06 | 2024-06-13 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| KR20210125298A (ko) | 2020-04-08 | 2021-10-18 | 주식회사 파마코스텍 | 테노포비어 알라펜아미드 헤미타르트레이트의 신규한 제조방법 |
| CN115605492B (zh) | 2020-04-21 | 2025-09-16 | 配体制药股份有限公司 | 核苷酸前药化合物 |
| CN115666570A (zh) | 2020-05-29 | 2023-01-31 | 吉利德科学公司 | 瑞德西韦治疗方法 |
| TW202417008A (zh) | 2020-06-24 | 2024-05-01 | 美商基利科學股份有限公司 | 1'-氰基核苷類似物及其用途 |
| CA3181690A1 (en) | 2020-06-25 | 2021-12-30 | Chienhung CHOU | Capsid inhibitors for the treatment of hiv |
| CN113970612B (zh) * | 2020-07-22 | 2023-08-01 | 北京四环制药有限公司 | 一种高效液相色谱法测定丙酚替诺福韦有关物质的方法 |
| EP4204421B1 (en) | 2020-08-27 | 2024-05-15 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| CN112336695B (zh) * | 2020-09-28 | 2023-01-03 | 华北制药华坤河北生物技术有限公司 | 一种富马酸丙酚替诺福韦片剂及其制备方法和有关物质的检测方法 |
| PL4244396T3 (pl) | 2020-11-11 | 2025-12-22 | Gilead Sciences, Inc. | Sposoby identyfikacji pacjentów z hiv wrażliwych na terapię przeciwciałami skierowanymi na miejsce wiązania cd4 gp120 |
| US11667656B2 (en) | 2021-01-27 | 2023-06-06 | Apotex Inc. | Crystalline forms of Tenofovir alafenamide |
| CN113075307B (zh) * | 2021-03-08 | 2025-03-11 | 瑞阳制药股份有限公司 | 富马酸丙酚替诺福韦异构体的检测方法 |
| CN113214322B (zh) * | 2021-04-30 | 2022-10-25 | 山东立新制药有限公司 | 替诺福韦绿色环保的制备方法 |
| WO2022251594A1 (en) * | 2021-05-27 | 2022-12-01 | Antios Therapeutics, Inc. | Pharmacokinetics and dose-related improvments in subjects treated with phosphoramidate clevudine prodrugs |
| DK4440702T3 (da) | 2021-12-03 | 2025-08-18 | Gilead Sciences Inc | Terapeutiske forbindelser til hiv-virusinfektion |
| CA3238270A1 (en) | 2021-12-03 | 2023-06-08 | Gediminas J. Brizgys | Therapeutic compounds for hiv virus infection |
| EP4440700A1 (en) | 2021-12-03 | 2024-10-09 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| CN114369120A (zh) * | 2022-01-28 | 2022-04-19 | 石家庄龙泽制药股份有限公司 | 一种丙酚替诺福韦关键中间体的制备方法 |
| TW202525810A (zh) | 2022-03-02 | 2025-07-01 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
| TW202446773A (zh) | 2022-04-06 | 2024-12-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| EP4547659A1 (en) | 2022-07-01 | 2025-05-07 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
| AU2023310177A1 (en) | 2022-07-21 | 2025-03-06 | Antiva Biosciences, Inc. | Compositions and dosage forms for treatment of hpv infection and hpv-induced neoplasia |
| US20240083984A1 (en) | 2022-08-26 | 2024-03-14 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
| US20240226130A1 (en) | 2022-10-04 | 2024-07-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| AU2024240009A1 (en) | 2023-03-17 | 2025-09-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for treatment of age-related macular degeneration |
| TW202444363A (zh) | 2023-04-19 | 2024-11-16 | 美商基利科學股份有限公司 | 殼體抑制劑之給藥方案 |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| CN121219281A (zh) | 2023-05-31 | 2025-12-26 | 吉利德科学公司 | 用于治疗hiv的化合物的固体形式 |
| WO2025029247A1 (en) | 2023-07-28 | 2025-02-06 | Gilead Sciences, Inc. | Weekly regimen of lenacapavir for the treatment and prevention of hiv |
| WO2025042394A1 (en) | 2023-08-23 | 2025-02-27 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| US20250120989A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| US20250127801A1 (en) | 2023-10-11 | 2025-04-24 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| WO2025080863A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| WO2025137245A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
| US20250289822A1 (en) | 2024-03-01 | 2025-09-18 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US20250296932A1 (en) | 2024-03-01 | 2025-09-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| US20250333424A1 (en) | 2024-03-01 | 2025-10-30 | Gilead Sciences, Inc. | Antiviral compounds |
| EP4640214A1 (en) | 2024-03-28 | 2025-10-29 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A tablet comprising tenofovir alafenamide monofumarate |
| WO2025260028A1 (en) | 2024-06-14 | 2025-12-18 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| CN118652277A (zh) * | 2024-08-19 | 2024-09-17 | 成都工业学院 | 一种用于治疗癌症疾病的化合物的制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999005150A1 (en) * | 1997-07-25 | 1999-02-04 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| US5977089A (en) * | 1996-07-26 | 1999-11-02 | Gilead Sciences, Inc. | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CS233665B1 (en) | 1983-01-06 | 1985-03-14 | Antonin Holy | Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene |
| CS263952B1 (en) | 1985-04-25 | 1989-05-12 | Holy Antonin | Remedy with antiviral effect |
| CS263951B1 (en) | 1985-04-25 | 1989-05-12 | Antonin Holy | 9-(phosponylmethoxyalkyl)adenines and method of their preparation |
| CS264222B1 (en) | 1986-07-18 | 1989-06-13 | Holy Antonin | N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them |
| US5650510A (en) | 1986-11-18 | 1997-07-22 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives |
| US5057301A (en) | 1988-04-06 | 1991-10-15 | Neorx Corporation | Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents |
| US5053215A (en) * | 1988-05-26 | 1991-10-01 | University Of Florida | NMR-assayable ligand-labelled trifluorothymidine containing composition and method for diagnosis of HSV infection |
| US5744600A (en) | 1988-11-14 | 1998-04-28 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Phosphonomethoxy carbocyclic nucleosides and nucleotides |
| US5688778A (en) | 1989-05-15 | 1997-11-18 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Nucleoside analogs |
| JP2648516B2 (ja) | 1989-07-27 | 1997-09-03 | ダイセル化学工業株式会社 | 立体異性体の分離法 |
| US5624898A (en) * | 1989-12-05 | 1997-04-29 | Ramsey Foundation | Method for administering neurologic agents to the brain |
| JP2925753B2 (ja) | 1990-02-23 | 1999-07-28 | ダイセル化学工業株式会社 | 光学異性体の分離方法 |
| US5302585A (en) | 1990-04-20 | 1994-04-12 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents |
| EP0452935B1 (en) * | 1990-04-20 | 1995-06-21 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents |
| SK280313B6 (sk) | 1990-04-24 | 1999-11-08 | �Stav Organick� Chemie A Biochemie Av �R | N-(3-fluór-2-fosfonylmetoxypropyl)deriváty purínov |
| US5627165A (en) * | 1990-06-13 | 1997-05-06 | Drug Innovation & Design, Inc. | Phosphorous prodrugs and therapeutic delivery systems using same |
| US5177064A (en) | 1990-07-13 | 1993-01-05 | University Of Florida | Targeted drug delivery via phosphonate derivatives |
| CS276072B6 (en) | 1990-08-06 | 1992-03-18 | Ustav Organicke Chemie A Bioch | (2R)-2-/DI(2-PROPYL)PHOSPHONYLMETHOXY/-3-p-TOLUENESULFONYLOXY -1- TRIMETHYLACETOXYPROPANE AND PROCESS FOR PREPARING THEREOF |
| WO1992002511A1 (en) | 1990-08-10 | 1992-02-20 | Bristol-Myers Squibb Company | Novel process for the preparation of nucleotides |
| DE69129650T2 (de) * | 1990-09-14 | 1999-03-25 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic, Prag/Praha | Wirkstoffvorläufer von Phosphonaten |
| US5827819A (en) * | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
| US5208221A (en) | 1990-11-29 | 1993-05-04 | Bristol-Myers Squibb Company | Antiviral (phosphonomethoxy) methoxy purine/pyrimidine derivatives |
| CZ284678B6 (cs) | 1991-05-20 | 1999-01-13 | Ústav Organické Chemie A Biochemie Avčr | Di(2-propyl)estery 1-fluor-2-fosfonomethoxy-3-p -toluensulfonyloxypropanů, způsob jejich přípravy a použití |
| US5498752A (en) | 1991-08-22 | 1996-03-12 | Daicel Chemical Industries, Ltd. | Process for recovering optical isomers and solvent, process for using solvent by circulation and process for reusing optical isomers in optical resolution |
| JP3010816B2 (ja) | 1991-08-22 | 2000-02-21 | ダイセル化学工業株式会社 | 光学分割における光学異性体と溶媒との回収方法、溶媒の循環使用方法、および光学異性体の再利用方法 |
| DE69218968T2 (de) | 1991-10-11 | 1997-10-09 | Inst Of Organic Chemistry And | Antivirale acyclische phosphonomethoxyalkyl substituierte, alkenyl und alkynyl purin und pyrimidin-derivate |
| US6057305A (en) | 1992-08-05 | 2000-05-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiretroviral enantiomeric nucleotide analogs |
| IL106998A0 (en) * | 1992-09-17 | 1993-12-28 | Univ Florida | Brain-enhanced delivery of neuroactive peptides by sequential metabolism |
| US6413949B1 (en) * | 1995-06-07 | 2002-07-02 | D-Pharm, Ltd. | Prodrugs with enhanced penetration into cells |
| US5798340A (en) * | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
| US5656745A (en) * | 1993-09-17 | 1997-08-12 | Gilead Sciences, Inc. | Nucleotide analogs |
| EP0719273B1 (en) | 1993-09-17 | 2010-11-03 | Gilead Sciences, Inc. | Nucleotide analogs |
| WO1995007919A1 (en) * | 1993-09-17 | 1995-03-23 | Gilead Sciences, Inc. | Method for dosing therapeutic compounds |
| GB9505025D0 (en) | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
| US5977061A (en) | 1995-04-21 | 1999-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | N6 - substituted nucleotide analagues and their use |
| EP0828749B1 (en) * | 1995-05-26 | 2003-07-16 | Genta Incorporated | Methods for the synthesis of organophosphorus derivatives |
| CA2239020A1 (en) | 1995-12-29 | 1997-07-10 | Norbert W. Bischofberger | Nucleotide analogs |
| US5717095A (en) * | 1995-12-29 | 1998-02-10 | Gilead Sciences, Inc. | Nucleotide analogs |
| US5874577A (en) * | 1996-04-03 | 1999-02-23 | Medichem Research, Inc. | Method for the preparing 9-12-(Diethoxyphosphonomethoxy)ethyl!adenine and analogues thereof |
| JP4033494B2 (ja) * | 1996-07-26 | 2008-01-16 | ギリヤド サイエンシーズ， インコーポレイテッド | ヌクレオチドアナログ |
| US5739314A (en) | 1997-04-25 | 1998-04-14 | Hybridon, Inc. | Method for synthesizing 2'-O-substituted pyrimidine nucleosides |
| US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| EP0996430B1 (en) | 1997-07-25 | 2002-11-27 | Gilead Sciences, Inc. | Nucleotide analog compositions |
| JP4465109B2 (ja) * | 1997-12-17 | 2010-05-19 | エンゾン ファーマシューティカルズ，インコーポレーテッド | アミノ及びヒドロキシル含有生物活性剤のポリマープロドラッグ |
| ATE212661T1 (de) * | 1998-01-23 | 2002-02-15 | Newbiotics Inc | Durch enzymkatalyse erhaltene therapeutische substanzen. |
| US6169078B1 (en) * | 1998-05-12 | 2001-01-02 | University Of Florida | Materials and methods for the intracellular delivery of substances |
| US6348185B1 (en) * | 1998-06-20 | 2002-02-19 | Washington University School Of Medicine | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| US6169879B1 (en) * | 1998-09-16 | 2001-01-02 | Webtv Networks, Inc. | System and method of interconnecting and using components of home entertainment system |
| GB9821058D0 (en) † | 1998-09-28 | 1998-11-18 | Univ Cardiff | Chemical compound |
| TWI230618B (en) * | 1998-12-15 | 2005-04-11 | Gilead Sciences Inc | Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same |
| NZ513450A (en) † | 1999-02-12 | 2004-03-26 | Glaxo Group Ltd | Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1R,cis)-4-(6-amino-9H-purin-9-yl)-2-cyclopentene- 1-methanol useful as antiviral agents |
| SI1301519T1 (sl) * | 2000-07-21 | 2015-07-31 | Gilead Sciences, Inc. | Predzdravila fosfonatnih nukleotidnih analogov in postopki za izbiro in izdelavo le-teh |
| EP1345956A2 (en) * | 2000-10-13 | 2003-09-24 | University of Lausanne | Intracellular delivery of biological effectors by novel transporter peptide sequences |
| US20020119433A1 (en) * | 2000-12-15 | 2002-08-29 | Callender Thomas J. | Process and system for creating and administering interview or test |
-
2001
- 2001-07-20 SI SI200131040T patent/SI1301519T1/sl unknown
- 2001-07-20 HR HRP20030047AA patent/HRP20030047B1/hr not_active IP Right Cessation
- 2001-07-20 HU HU0301307A patent/HU230960B1/hu active Protection Beyond IP Right Term
- 2001-07-20 HR HRP20160074AA patent/HRP20160074B1/hr not_active IP Right Cessation
- 2001-07-20 PT PT1961695T patent/PT1301519E/pt unknown
- 2001-07-20 UA UA2003021482A patent/UA75889C2/uk unknown
- 2001-07-20 EA EA200300188A patent/EA004926B1/ru active Protection Beyond IP Right Term
- 2001-07-20 MX MXPA03000587A patent/MXPA03000587A/es active IP Right Grant
- 2001-07-20 WO PCT/US2001/023104 patent/WO2002008241A2/en not_active Ceased
- 2001-07-20 AU AU2001282941A patent/AU2001282941C1/en active Active
- 2001-07-20 JP JP2002514146A patent/JP4651264B2/ja not_active Expired - Lifetime
- 2001-07-20 SI SI200131061T patent/SI2682397T1/sl unknown
- 2001-07-20 US US10/333,107 patent/US20040018150A1/en not_active Abandoned
- 2001-07-20 NZ NZ536942A patent/NZ536942A/xx not_active IP Right Cessation
- 2001-07-20 CA CA2725819A patent/CA2725819C/en not_active Expired - Lifetime
- 2001-07-20 EP EP13164300.9A patent/EP2682397B1/en not_active Revoked
- 2001-07-20 PT PT131643009T patent/PT2682397T/pt unknown
- 2001-07-20 CZ CZ2013-310A patent/CZ304734B6/cs not_active IP Right Cessation
- 2001-07-20 NZ NZ535408A patent/NZ535408A/en not_active IP Right Cessation
- 2001-07-20 CA CA2893174A patent/CA2893174A1/en not_active Abandoned
- 2001-07-20 IL IL15365801A patent/IL153658A0/xx active Protection Beyond IP Right Term
- 2001-07-20 ES ES01961695T patent/ES2536972T5/es not_active Expired - Lifetime
- 2001-07-20 ES ES13164300.9T patent/ES2627903T3/es not_active Expired - Lifetime
- 2001-07-20 KR KR1020067020061A patent/KR100749160B1/ko not_active Expired - Lifetime
- 2001-07-20 DK DK01961695.2T patent/DK1301519T4/da active
- 2001-07-20 US US09/909,560 patent/US20020119443A1/en not_active Abandoned
- 2001-07-20 PL PL360490A patent/PL213214B1/pl unknown
- 2001-07-20 AP APAP/P/2003/002724A patent/AP1466A/en active
- 2001-07-20 DK DK13164300.9T patent/DK2682397T3/da active
- 2001-07-20 NZ NZ523438A patent/NZ523438A/en not_active IP Right Cessation
- 2001-07-20 OA OA1200300003A patent/OA12393A/en unknown
- 2001-07-20 EP EP01961695.2A patent/EP1301519B2/en not_active Expired - Lifetime
- 2001-07-20 LT LTEP13164300.9T patent/LT2682397T/lt unknown
- 2001-07-20 CZ CZ2003-413A patent/CZ304886B6/cs unknown
- 2001-07-20 KR KR1020037000872A patent/KR100767432B1/ko not_active Expired - Lifetime
- 2001-07-20 AU AU8294101A patent/AU8294101A/xx active Pending
- 2001-07-20 CN CNB018131611A patent/CN1291994C/zh not_active Expired - Lifetime
- 2001-07-20 BR BR0112646A patent/BRPI0112646B8/pt active IP Right Grant
- 2001-07-20 CA CA2416757A patent/CA2416757C/en not_active Expired - Lifetime
- 2001-07-20 CN CNB2004100978453A patent/CN100402539C/zh not_active Expired - Lifetime
- 2001-07-20 EP EP17160970.4A patent/EP3235823A1/en not_active Withdrawn
- 2001-07-20 EE EEP200300029A patent/EE05366B1/xx active Protection Beyond IP Right Term
- 2001-07-20 TR TR2003/00055T patent/TR200300055T2/xx unknown
-
2002
- 2002-12-19 ZA ZA2002/10271A patent/ZA200210271B/en unknown
-
2003
- 2003-01-17 IS IS6689A patent/IS2985B/is unknown
- 2003-01-20 NO NO20030270A patent/NO336718B1/no active Protection Beyond IP Right Term
- 2003-01-28 US US10/354,207 patent/US20030219727A1/en not_active Abandoned
- 2003-02-19 BG BG107572A patent/BG66037B1/bg unknown
-
2004
- 2004-02-24 US US10/785,497 patent/US20060024659A1/en not_active Abandoned
- 2004-03-11 US US10/798,692 patent/US7390791B2/en not_active Expired - Lifetime
-
2005
- 2005-01-06 US US11/031,252 patent/US20050124585A1/en not_active Abandoned
- 2005-01-06 US US11/031,228 patent/US20050159392A1/en not_active Abandoned
- 2005-01-06 US US11/031,250 patent/US20050124583A1/en not_active Abandoned
- 2005-01-06 US US11/031,251 patent/US20050124584A1/en not_active Abandoned
- 2005-10-18 AU AU2005225039A patent/AU2005225039B2/en not_active Expired
-
2008
- 2008-04-28 US US12/110,829 patent/US7803788B2/en not_active Expired - Fee Related
- 2008-10-16 JP JP2008267991A patent/JP5063554B2/ja not_active Expired - Lifetime
-
2010
- 2010-04-16 JP JP2010095542A patent/JP5111551B2/ja not_active Expired - Lifetime
-
2011
- 2011-03-08 JP JP2011050854A patent/JP2011140506A/ja not_active Withdrawn
-
2012
- 2012-04-23 NO NO20120466A patent/NO20120466L/no not_active Application Discontinuation
-
2013
- 2013-12-20 NO NO20131717A patent/NO20131717L/no unknown
-
2015
- 2015-07-10 NO NO20150909A patent/NO20150909L/no not_active Application Discontinuation
-
2016
- 2016-04-05 LT LTPA2016009C patent/LTC1301519I2/lt unknown
- 2016-04-07 BE BE2016C018C patent/BE2016C018I2/fr unknown
- 2016-04-11 FR FR16C0013C patent/FR16C0013I2/fr active Active
- 2016-04-12 CY CY2016008C patent/CY2016008I1/el unknown
- 2016-04-14 LU LU93029C patent/LU93029I2/xx unknown
- 2016-04-19 NO NO2016006C patent/NO2016006I1/no unknown
- 2016-04-22 NL NL300803C patent/NL300803I2/nl unknown
-
2017
- 2017-06-28 CY CY20171100687T patent/CY1119411T1/el unknown
-
2018
- 2018-03-09 HK HK18103347.4A patent/HK1243711A1/en unknown
-
2019
- 2019-05-09 HU HUS1900027C patent/HUS1900027I1/hu unknown
-
2023
- 2023-02-03 NO NO2023006C patent/NO2023006I1/no unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5977089A (en) * | 1996-07-26 | 1999-11-02 | Gilead Sciences, Inc. | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
| WO1999005150A1 (en) * | 1997-07-25 | 1999-02-04 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CZ304734B6 (cs) | Způsob přípravy 9-[2-(fosfonomethoxy)propyl]adeninu a 9-[2-(fosfonomethoxy)ethyl]adeninu | |
| US8846896B2 (en) | Methods of preparing substituted nucleotide analogs | |
| FI90429B (fi) | Menetelmä uusien terapeuttisesti käyttökelpoisten adenosiinijohdannaisten valmistamiseksi ja välituotteita | |
| KR20180041225A (ko) | GalNAc 클러스터 포스포라미다이트 | |
| TR201816146T4 (tr) | Meti̇l-{4,6-di̇ami̇no-2-[1-(2-florobenzi̇l)-1h-pi̇razolo[3,4-b]pi̇ri̇di̇n-3-i̇l]pi̇ri̇mi̇di̇n-5-i̇lmeti̇l}karbamatin farmasöti̇k etken madde olarak kullanima yöneli̇k olarak üreti̇lmesi̇ne yöneli̇k yöntem. | |
| GB2134907A (en) | Isomeric o-phosphonylmethyl derivatives of enantiomeric and racemic vicinal diols and method of preparing them | |
| CN101657462A (zh) | 卡培他滨的制备方法及其中间体 | |
| WO2014033688A1 (en) | A process for the preparation of (r)-9-[2-(phosphonometh-oxy)propyl]adenine (pmpa) | |
| EP0521923B1 (en) | Process for producing nucleosides, and analogs therof | |
| EP3131910B1 (en) | Use of a 1,3,5-triazin-2-yl phosphoramidate compound in the synthesis of sofosbuvir | |
| CZ293546B6 (cs) | Způsob štěpení racemátů ketaminu | |
| EP2181102A1 (en) | Process for controlled crystal size in 1,2-substituted 3,4-dioxo-1-cyclobutene compounds | |
| JP2012533618A (ja) | フルオロシチジン誘導体の製造プロセス | |
| HUP0200839A2 (en) | Novel synthesis and crystallization of piperazine ring-containing compounds and pharmaceutical compositions containing them | |
| JP3884779B2 (ja) | ２’，３’−ジデヒドロ−２’，３’−ジデオキシヌクレオシド類の大量製造法 | |
| US3029239A (en) | Basic substituted 1-and 7-alkylxanthines or salts thereof | |
| JP3901321B2 (ja) | リボフラビン−５’−リン酸またはそのナトリウム塩の製造法 | |
| WO2008065490A2 (en) | Process for the preparation of atazanavir | |
| CN1910194B (zh) | 海绵核苷的合成 | |
| KR101247653B1 (ko) | 아데포비어 디피복실 제조방법 | |
| KR101195631B1 (ko) | ９-［２-(포스포노메톡시)에틸］아데닌의 개선된 제조방법 | |
| EP1018509A1 (en) | A process for preparing 4-amino-1,2,4-triazolin-5-ones | |
| EP4373494A1 (en) | Methods for preparing bisphosphocins | |
| CN100528893C (zh) | 依托泊苷磷酸酯的制备方法 | |
| CN107759483B (zh) | 一种甲氨基取代的环戊烷甲酸烷基酯的制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Patent expired |
Effective date: 20210720 |